In December 2015, Evecxia and Duke University School of Medicine entered into a worldwide license agreement granting Evecxia the exclusive right to develop and commercialize certain issued patents and pending patent applications involving 5-hydroxytryptophan (5-HTP).
In April 2018, the above-mentioned license agreement was expanded to include pending patent applications involving 5-HTP in combination with other pharmacological agents.
In September 2018, Evecxia and Duke-National University of Singapore Medical School, the National University Hospital of Singapore, and the Nanyang Technological University, entered into an exclusive worldwide license agreement granting Evecxia the exclusive right to develop and commercialize pending patent applications involving 5-HTP.
Evecxia's lead candidate, EVX-101, results from a collaboration with Duke-NUS Medical School, Nanyang Technological University and National University Hospital, Singapore.
With our unsurpassed knowledge and experience with 5-HTP serving as a hub for additional scientific exploration and development into multiple complimentary areas of unmet need, we seek value-added partnerships and collaborations with academic and corporate partners across therapeutic areas to work with us to improve lives, restore hope!